Payment overview · 2025
General Payments
$676.20
39 reported records · 7 companies
Healthcare provider profile · identity verified
Stanley J Conhon, MD
Allopathic & Osteopathic Physicians|Family Medicine · DAVISON, MI · NPI 1487642575
Verified facts
What the public records show
CMS Open Payments records show Stanley J Conhon, MD received $676.20 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $256.59 | 38.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.70 | 29.5% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.88 | 10.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.46 | 8.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.06 | 7.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.17 | 3.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.34 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $676.20 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $166.22 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.95 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $90.37 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $62.75 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.75 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.46 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $50.60 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.06 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.06 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 62 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
185 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 256 |
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 146 |
| Losartan Potassium | Losartan Potassium | 448 | 139 |
| Omeprazole | Omeprazole | 427 | 131 |
| Lisinopril | Lisinopril | 406 | 126 |
| Metformin Hcl | Metformin Hcl | 404 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 128 |
| Gabapentin | Gabapentin | 320 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 303 | 96 |
| Citalopram Hbr | Citalopram Hydrobromide | 302 | 83 |
| Simvastatin | Simvastatin | 293 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 185 | 50 |
| Pregabalin | Pregabalin | 179 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 49 |
| Prednisone | Prednisone | 175 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 54 |
| Potassium Chloride | Potassium Chloride | 172 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 55 |
| Montelukast Sodium | Montelukast Sodium | 163 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 52 |
| Furosemide | Furosemide | 152 | 53 |
| Mounjaro | Tirzepatide | 148 | 29 |
| Eliquis | Apixaban | 147 | 39 |
| Jardiance | Empagliflozin | 144 | 40 |
| Ozempic | Semaglutide | 141 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 141 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 26 |
| Alprazolam | Alprazolam | 120 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 32 |
| Aripiprazole | Aripiprazole | 112 | 29 |
| Trazodone Hcl | Trazodone Hcl | 108 | 30 |
| Azithromycin | Azithromycin | 107 | 86 |
| Meloxicam | Meloxicam | 107 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 106 | 34 |
| Ibuprofen | Ibuprofen | 105 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 24 |
| Allopurinol | Allopurinol | 101 | 26 |
| Carvedilol | Carvedilol | 98 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 25 |
| Sertraline Hcl | Sertraline Hcl | 97 | 29 |
| Glimepiride | Glimepiride | 92 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 89 | 40 |
| Ezetimibe | Ezetimibe | 80 | 27 |
| Naproxen | Naproxen | 80 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 20 |
| Cephalexin | Cephalexin | 65 | 42 |
| Donepezil Hcl | Donepezil Hcl | 64 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 18 |
| Rybelsus | Semaglutide | 62 | 18 |
| Baclofen | Baclofen | 59 | 12 |
| Doxepin Hcl | Doxepin Hcl | 59 | 15 |
| Atenolol | Atenolol | 58 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 17 |
| Meclizine Hcl | Meclizine Hcl | 51 | 21 |
| Varenicline Tartrate | Varenicline Tartrate | 51 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 17 |
| Cilostazol | Cilostazol | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 50 | 17 |
| Alendronate Sodium | Alendronate Sodium | 49 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 22 |
| Glipizide | Glipizide | 48 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 14 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Nifedipine Er | Nifedipine | 47 | 18 |
| Fenofibrate | Fenofibrate | 46 | 12 |
| Buspirone Hcl | Buspirone Hcl | 45 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 26 |
| Famotidine | Famotidine | 45 | 13 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 17 |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 11 |
| Topiramate | Topiramate | 41 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 39 | 13 |
| Fenofibrate | Fenofibrate,micronized | 38 | 11 |
| Glipizide Er | Glipizide | 38 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 13 |
| Valacyclovir | Valacyclovir Hcl | 38 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 12 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | 12 |
| Finasteride | Finasteride | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | 12 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Lactulose | Lactulose | 23 | 13 |
| Primidone | Primidone | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Metolazone | Metolazone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Wegovy | Semaglutide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $676.20 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, VRAYLAR, Veozah, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error